Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinoma-Reference-Cited by-同舟云学术

Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinoma

Published:2022-09 Issue: Volume:153 Page:113540
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Lin Zu-Yau,Yeh Ming-Lun,Huang Ching-I.,Liang Po-Cheng,Hsu Po-Yao,Chen Shinn-Cherng,Huang Chung-Feng,Huang Jee-Fu,Dai Chia-Yen,Yu Ming-Lung,Chuang Wan-Long

Funder

Kaohsiung Medical University Chung-Ho Memorial Hospital

Ministry of Science and Technology of the People's Republic of China

Ministry of Science and Technology, Taiwan

Ministry of Science and Technology, Croatia

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference33 articles.

1. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma;De Mattia;World J. Gastroenterol.,2019

2. Advances in immunotherapy for hepatocellular carcinoma;Sangro;Nat. Rev. Gastroenterol. Hepatol.,2021

3. Evolution of systemic treatment for advanced hepatocellular carcinoma;Wu;Kaohsiung J. Med. Sci.,2021

4. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways;Xu;Cancer Lett.,2016

5. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma;Solms;Eur. J. Pharm. Sci.,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Colchicine-mediated selective autophagic degradation of HBV core proteins inhibits HBV replication and HBV-related hepatocellular carcinoma progression;Cell Death Discovery;2024-08-06

2. Paris saponin VII inhibits triple-negative breast cancer by targeting the MEK/ERK/STMN1 signaling axis;Phytomedicine;2024-07

3. Metabolomics reveals that sulfotransferase 1 may regulate colchicine-induced liver injury;Chemico-Biological Interactions;2023-12

4. Dose Consideration of Lenvatinib’s Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy;Cancers;2023-10-22

5. Colchicine inhibits the proliferation and promotes the apoptosis of papillary thyroid carcinoma cells likely due to the inhibitory effect on HDAC1;Biochemical and Biophysical Research Communications;2023-10